Terbium-161 (Tb-161) is emerging as a next-generation therapeutic radionuclide that augments conventional beta-particle therapy with a potent payload of short-range conversion and Auger electrons, offering the potential to eradicate isolated tumor cells and micrometastatic disease with unprecedented precision. At Protheragen, our radiochemistry team is equipped to support your Tb-161 radiolabeling needs—from chelator selection and conjugation optimization to GMP-compliant production—accelerating your radiopharmaceutical pipeline from concept to clinic.
Tb-161 is a medium-energy beta-emitting radiolanthanide with a physical half-life of approximately 6.89 days, decaying to stable dysprosium-161. Its decay scheme closely mirrors that of the clinically established lutetium-177 (Lu-177), emitting beta-minus particles with a mean energy of ~154 keV alongside gamma photons at 48.9 keV and 74.6 keV suitable for SPECT imaging. What distinguishes Tb-161 from its lanthanide counterpart is the co-emission of a substantial yield of low-energy conversion electrons and Auger electrons—particles with ultra-short path lengths that deposit energy within nanometers to micrometers of the decay site. Monte Carlo simulations and preclinical dosimetry have demonstrated that these short-range emissions can deliver up to 3.6-fold higher absorbed doses to single cells and 1.8-fold higher doses to 100-micrometer micrometastases compared to Lu-177, making Tb-161 particularly attractive for treating disseminated, small-volume disease where conventional beta therapy falls short.
Fig 1. Scheme of the separation and purification process of 161Tb. (Skálová, Marie, et al., 2026)
From a radiochemical perspective, Tb-161 leverages the same trivalent coordination chemistry as Lu-177, enabling straightforward isotope-switching of established DOTA-conjugated vectors without requiring extensive ligand re-engineering. Common chelators such as DOTA, DOTA-GA, and NETA have all demonstrated high-yield Tb-161 labeling under mild conditions (e.g., 40 degrees C), with radiochemical purities exceeding 98%. This chemical parallelism means that preclinical and clinical workflows developed for Lu-177—including quality control protocols, stability assessments in human serum, and in vivo biodistribution methodologies—can be adapted for Tb-161 with minimal modification, lowering the translational barrier for developers seeking to incorporate this isotope into their therapeutic programs.
The following comparison highlights the key physical, radiochemical, and clinical distinctions between Tb-161 and Lu-177, underscoring why Tb-161 is being positioned as a complementary—or potentially superior—therapeutic isotope for specific indications.
| Parameter | Lutetium-177 (Lu-177) | Terbium-161 (Tb-161) |
|---|---|---|
| Half-life | 6.65 days | 6.89-6.98 days |
| Decay mode | Beta-minus (100%) | Beta-minus + conversion electrons + Auger electrons |
| Mean beta energy | ~133 keV | ~154 keV |
| Gamma for imaging | 113 keV (6.4%), 208 keV (11%) | 48.9 keV (17%), 74.6 keV (10.2%) |
| Conversion electrons | ~13.5 keV/decay | ~39.3 keV/decay |
| Auger + Coster-Kronig electrons | ~1.1 keV/decay | ~8.9 keV/decay |
| Energy deposition (100 um sphere) | 24.5 Gy | 44.5 Gy |
| Energy deposition (10 um cell) | 3.9 Gy | 14.1 Gy |
| Chelators used | DOTA, derivatives | DOTA, DOTA-GA, NETA |
| Optimal labeling pH | 4.0-5.5 | 4.0-5.5 |
| Labeling temperature | 90-95 C (standard) | 40-95 C (mild conditions feasible) |
| Radiochemical purity | >95% | >98% (reported) |
| Clinical status | FDA/EMA approved (Lutathera, Pluvicto) | Investigational (clinical trials ongoing) |
| Primary advantage | Established supply chain, proven efficacy | Superior micrometastatic cell kill, lower administered activity potential |
| Dose per unit activity (tumor) | Baseline | ~1.4x higher than Lu-177 |
| Equivalent activity for same kidney dose | 7,400 MBq/cycle | ~5,300-5,400 MBq/cycle |
Protheragen is a full-service Radiopharmaceutical CRDMO and CRO dedicated to bridging the gap between radiochemical innovation and clinical application. Our integrated platform spans preclinical radiopharmaceutical development, in vitro and in vivo evaluation, IIT clinical study management, and regulatory-compliant manufacturing. Whether you are developing a novel Tb-161-labeled PSMA ligand, a somatostatin receptor antagonist, or an antibody-based radioimmunoconjugate, Protheragen provides the radiochemistry expertise, analytical infrastructure, and quality systems necessary to advance your compound efficiently and rigorously through each development milestone.
We evaluate and optimize bifunctional chelators—including DOTA, DOTA-GA, CHX-A''-DTPA, and NETA—for your specific biomolecule. Our team assesses conjugation efficiency, linker stability, and immunoreactivity retention to ensure the final construct maintains target affinity after radiolabeling.
From initial proof-of-concept labeling to robust, reproducible protocols, we develop and validate Tb-161 radiolabeling conditions tailored to heat-sensitive biologics (e.g., antibodies, single-domain antibodies) and small-molecule ligands alike. Parameters including pH, temperature, reaction time, and specific activity are systematically optimized to achieve radiochemical yields exceeding 98% with molar activities suitable for therapeutic dosing.
Every Tb-161 batch undergoes comprehensive QC encompassing radiochemical purity (iTLC, HPLC, UPLC), radionuclidic purity (gamma spectrometry), specific activity determination, and stability profiling in physiologically relevant media (human serum, PBS) at 37 degrees C over extended timeframes. We also perform endotoxin, sterility, and bacterial viability testing where GMP compliance is required.
Our biology team conducts cell-based uptake, internalization, and cytotoxicity assays using Tb-161-labeled agents, alongside in vivo biodistribution, dosimetry, and efficacy studies in xenograft or patient-derived tumor models. We offer head-to-head comparative studies against Lu-177 counterparts to generate the preclinical evidence package required for IND-enabling submissions.
Our Tb-161 radiolabeling workflow is designed to ensure reproducibility, regulatory compliance, and seamless scalability—from milligram-scale research batches to clinical-grade production. Each stage is executed under rigorous quality oversight with full traceability.
Step 1: Project Consultation & Feasibility Assessment
We begin with a detailed consultation to understand your target indication, vector molecule, and desired specific activity. Our radiochemists evaluate chelator compatibility and develop a customized labeling strategy aligned with your preclinical or clinical objectives.
Step 2: Chelator Conjugation & Precursor Synthesis
The selected bifunctional chelator is conjugated to your targeting vector (peptide, antibody, small molecule, or nanoparticle) via amine, thiol, or click-chemistry approaches. The resulting precursor is purified and characterized by mass spectrometry and HPLC to confirm conjugation efficiency.
Step 3: Tb-161 Radiolabeling & Reaction Optimization
Tb-161 chloride is combined with the chelator-vector conjugate under optimized conditions (pH 4.0-5.5, temperature 40-95 degrees C depending on vector heat sensitivity, 10-30 minutes). Reaction parameters are fine-tuned to maximize radiochemical yield and molar activity while preserving vector integrity.
Step 4: Purification & Quality Control
The crude reaction mixture is purified by solid-phase extraction, size-exclusion chromatography, or HPLC to remove unbound Tb-161. Comprehensive QC is performed, including radiochemical purity (>=98%), radionuclidic identity (gamma spectroscopy), specific activity, and in vitro stability in human serum at 37 degrees C.
Step 5: Stability Profiling & Formulation
Radiolabeled products are subjected to long-term stability studies under storage and physiological conditions. Formulation buffers are optimized to maintain radiochemical integrity, and radioprotectants are evaluated to mitigate radiolysis over the product shelf life.
Step 6: Documentation & Technology Transfer
A complete technology transfer package—including batch records, analytical methods, validation data, and regulatory CMC documentation—is delivered to support your IND/CTA submission or internal manufacturing scale-up.
Ready to explore how Tb-161 can elevate your targeted radionuclide therapy program? Reach out to us today to discuss your project requirements, request a feasibility assessment, or schedule a consultation with our radiochemistry team. Whether you are at the earliest stages of vector selection or preparing for clinical translation, Protheragen is here to help you harness the full therapeutic potential of Tb-161.
Reference